ENDRA Life Sciences Inc. Stock

Equities

NDRA

US29273B3024

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-06-06 pm EDT 5-day change 1st Jan Change
0.1153 USD -16.99% Intraday chart for ENDRA Life Sciences Inc. -58.84% -94.56%
Sales 2024 * 200K Sales 2025 * 1M Capitalization 1.53M
Net income 2024 * -11M Net income 2025 * -12M EV / Sales 2024 * 7.66 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.53 x
P/E ratio 2024 *
-0.11 x
P/E ratio 2025 *
-0.11 x
Employees 21
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.85%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.86%
1 week-56.82%
Current month-57.14%
1 month-64.71%
3 months-89.96%
6 months-91.40%
Current year-94.56%
More quotes
1 week
0.07
Extreme 0.0692
0.31
1 month
0.07
Extreme 0.0692
0.34
Current year
0.07
Extreme 0.0692
1.95
1 year
0.07
Extreme 0.0692
2.79
3 years
0.07
Extreme 0.0692
48.80
5 years
0.07
Extreme 0.0692
62.00
10 years
0.07
Extreme 0.0692
117.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 14-12-31
Director of Finance/CFO 38 21-06-17
Chief Tech/Sci/R&D Officer 55 06-12-31
Members of the board TitleAgeSince
Director/Board Member 57 13-06-30
Director/Board Member 62 07-12-31
Director/Board Member 69 14-12-31
More insiders
Date Price Change Volume
24-06-06 0.1153 -16.99% 53,194,301
24-06-05 0.1389 +63.41% 485,625,524
24-06-04 0.085 -60.83% 72,337,768
24-06-03 0.217 -19.33% 622,458
24-05-31 0.269 -3.96% 301,267

Delayed Quote Nasdaq, June 06, 2024 at 04:00 pm EDT

More quotes
ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology which characterizes tissue similar to a magnetic resonance imaging (MRI). The Company's TAEUS technology uses radio frequency (RF) pulses to stimulate tissues, using a small fraction (less than 1%) of the amount of energy that would be transmitted into the body during an MRI scan. The use of RF energy allows its TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD), a chronic liver disease spectrum. It is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1389 USD
Average target price
10 USD
Spread / Average Target
+7,099.42%
Consensus